The aim of this updated guideline is to provide comprehensive and timely evidence-based
recommendations on the prevention of future stroke among survivors of ischemic stroke or …

Background The risk of stroke varies considerably across different groups of patients with
atrial fibrillation (AF). Antithrombotic prophylaxis for stroke is associated with an increased risk …

Objectives : The purpose of this study was to develop a risk stratification score to predict
warfarin-associated hemorrhage. Background : Optimal decision making regarding warfarin use …

This chapter about antithrombotic therapy in atrial fibrillation (AF) is part of the American
College of Chest Physicians Evidence-Based Guidelines Clinical Practice Guidelines (8th …

Background The clinical utility of genotype-guided (pharmacogenetically based) dosing of
warfarin has been tested only in small clinical trials or observational studies, with equivocal …

Background: Guidelines recommend warfarin use in patients with atrial fibrillation solely on
the basis of risk for ischemic stroke without antithrombotic therapy. These guidelines rely on …

Background: The risk for atrial fibrillation–associated stroke increases at low anticoagulation
intensities. However, higher intensities increase hemorrhage risk. Optimal use of warfarin …

OBJECTIVES: Little is known about the outcomes of patients who have hemorrhagic
complications while receiving warfarin therapy. We examined the rates of death and disability …

Background— Previous studies provide conflicting results about whether women are at
higher risk than men for thromboembolism in the setting of atrial fibrillation (AF). We examined …

Background— Atrial fibrillation (AF) substantially increases the risk of ischemic stroke, but
this risk varies among individual patients with AF. Existing risk stratification schemes have …